[wpml_language_selector_widget]

Patient Support Strategies

Patients with a history of cutaneous squamous cell carcinoma (cSCC) face a significantly increased risk of recurrence and the development of other skin cancers. Regular follow-up and long-term surveillance are crucial, alongside educating patients about sun protection and self-examination.1

The risk of recurrence is substantial, with 13-50% developing another SCC within five years, a 10-fold increase compared to the general population.2–4 Therefore, long-term follow-up and patient education are essential, especially since 70-80% of cutaneous SCC recurrences occur within two years of initial therapy.3,4 After a cSCC diagnosis, regular in-office screenings become essential. Patients are advised to have these screenings at least once yearly to detect any new primary skin cancers, including cSCC, BCC, and melanoma. In a prospective cohort study, Wehner et al. discovered that the likelihood of developing another non-melanoma skin cancer (NMSC) within 5 years after being diagnosed with the first one was 40.7%. The likelihood increased to 59.6% at 10 years. Additionally, after being diagnosed with more than one NMSC, the probability of developing another NMSC increased to 82% after 5 years and 91.2% after 10 years.5

Patient Education1

Patient education is a critical component of follow-up care. It is important for patients to understand the necessity of sun protection, regular self-examination, and awareness of treatment options.

Symptom Management6

Symptom management aims to improve the quality of life for cSCC patients through a combination of treatments and supportive care.

  • Pain Management: Involves the use of paracetamol, NSAIDs, and opioids, with morphine gel useful for smaller wounds
  • Wound Care:
    • Regular rinsing with disinfectant solutions
    • Using silver and honey dressings to reduce malignant fungating wound discharge and malodor
    • Applying zinc oxide paste or silicone gel to prevent skin maceration
  • Palliative Treatments: Local surgery, radiotherapy (RT), or electrochemotherapy can help control tumor extension and relieve symptoms. RT is often used for pain relief and to stop hemorrhage in functional areas

Coping Strategies and Mental Health

The physical and psychological impact of cSCC and its treatment can be significant. Coping strategies and mental health support are vital for improving patients’ quality of life.

  • Impact on Quality of Life: Disease symptoms, treatment side-effects, and concerns about appearance can cause substantial distress7
  • Supportive Care8:
    • Support groups and counseling sessions with psychologists or psychiatrists
    • Medication and integrative health therapies such as acupuncture to relieve pain and other symptoms
    • Stress-reducing activities like massage therapy and yoga
    • Encouraging a healthy diet and regular exercise

Considerations in High-Risk Patients1

High-risk patients should treat actinic keratoses (AKs) promptly to prevent the development of subsequent invasive tumors.1

Preventive measures are essential for high-risk patients to reduce the incidence of new SCCs.

  • Prophylactic Treatments:
    • Oral Retinoids: Acitretin, isotretinoin, and etretinate can significantly reduce new SCCs in high-risk patients
    • Nicotinamide: Shown to reduce the 12-month rate of new SCCs by 30% and new BCCs by 20%
  • Patient Education:
    • Ongoing education on the importance of sun protection and regular skin checks
    • Behavioral interventions to improve sun protection practices

Healthcare providers can help cSCC patients manage their condition more effectively and improve their overall quality of life by understanding the importance of patient education, symptom management, and coping strategies. Regular education on sun protection, self-examination, and awareness of the risks associated with delayed treatment can significantly improve outcomes.

References

  1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology.Squamous Cell Skin Cancer. Version 1.2024. (https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf).
  2. Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA. 1992;267:3305-3310. PMID: 1597912
  3. Flohil SC, van der Leest RJT, Arends LR, de Vries E, Nijsten T. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta-analysis. Eur J Cancer. 2013;49:2365-2375. doi:10.1016/j.ejca.2013.03.010
  4. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: A critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524-1530. doi:10.1001/archderm.136.12.1524
  5. Wehner MR, Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Chren MM. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol. 2015;151:382-388. doi:10.1001/jamadermatol.2014.3307
  6. Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. Eur J Cancer. 2023;193:113252. doi:10.1016/j.ejca.2023.113252
  7. Work Group; Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-578. doi:10.1016/j.jaad.2017.10.007
  8. NYU Langone Health. Support for Basal & Squamous Cell Skin Cancers. (https://nyulangone.org/conditions/basal-squamous-cell-skin-cancers/support).

All URLs accessed June 25, 2024.

Pin It on Pinterest

Directory
Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers